Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00708799 · ClinicalTrials.gov registry record · Phase 2

Efficacy of Macrolide Immunomodulation in Severe Sepsis.

A Phase 2 study, sponsored by VA Office of Research and Development.

Terminated
Registry status
Phase 2
Development phase
100
Enrollment target

NCT00708799: Clinical Trial Phase 2 study, sponsored by VA Office of Research and Development.

NCT00708799 is a Phase 2 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00708799, a Phase 2 study, was terminated before completion, sponsored by VA Office of Research and Development.

TERMINATED
Registry status
Phase 2
Development phase
100 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether macrolide treatment of patients with severe sepsis has an advantageous immunomodulatory and clinical effect compared to severe septic patients without macrolide therapy. Our main hypothesis is macrolide use in addition to standard therapy in severe septic patients has an advantageous immunomodulatory and clinical effect compared to patients with severe sepsis not treated with a macrolide.

Interventions

  • OTHER Azithromycin on admission - not enrolled in the RCT

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2007-11
Est. Completion 2013-11
Phase Phase 2
VA Office of Research and Development

1,668 total trials

Why NCT00708799 stopped before completion

NCT00708799 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).

The record links to 0 conditions, and to 1 intervention - of which Azithromycin on admission - not enrolled in the RCT is the first listed.

NCT00708799 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00708799 about?

NCT00708799 is a clinical study titled "Efficacy of Macrolide Immunomodulation in Severe Sepsis.". The purpose of this study is to determine whether macrolide treatment of patients with severe sepsis has an advantageous immunomodulatory and clinical effect compared to severe septic patients without macrolide therapy. Our main hypothesis is macrolide use in addition to standard therapy in severe s...

What is the current status of trial NCT00708799?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2007-11. Estimated completion is 2013-11.

What interventions are being tested in trial NCT00708799?

The interventions under investigation include: Azithromycin on admission - not enrolled in the RCT (OTHER).

Who is sponsoring clinical trial NCT00708799?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00708799's enrollment target sits among peer trials

100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00708799, the US trial registry maintained by the National Library of Medicine. NCT00708799 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.